The European Patent Office (EPO) has granted patent EP4635945A1 for a specific crystal form of the drug Proximod, along with its preparation method and intended uses. This patent, published on March 18, 2026, covers intellectual property related to pharmaceutical development and manufacturing.

This grant signifies a new intellectual property right for the applicants, Jiankuan (Suzhou) Biotechnology Co., Ltd and the Institute of Materia Medica, Chinese Academy of Medical Sciences. Companies operating in the pharmaceutical sector, particularly those involved in the development or potential manufacturing of Proximod or similar compounds, should note this patent to ensure compliance with intellectual property laws and avoid infringement.